Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Misses Expectations By $0.19 EPS

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19), FiscalAI reports. The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Second-quarter revenue reached a record $92.1 million, with net product revenue up 34% year over year to $91 million; adjusted EBITDA increased more than 50% to $19.3 million.
• RECORLEV revenue surged 81% to $56.8 million, supported by record referrals, new patient starts, and prescriber growth. Management expects the expanded commercial team to contribute further in the second half.
• Xeris raised and narrowed full-year 2026 revenue guidance to $385 million-$390 million, citing sustained portfolio momentum and an expected rebound in Gvoke, while KEVEYIS received a patent allowance that could extend protection through at least 2039.
• The company fully retired its $34 million of convertible debt in July, eliminating approximately $3 million in annual interest expense and simplifying the balance sheet, although the transaction generated a one-time, non-cash GAAP charge of about $31 million in the second quarter.
• Xeris plans to increase full-year SG&A by approximately $50 million and R&D by $25 million versus 2025, primarily to support RECORLEV expansion and the planned year-end Phase III start for XP-8121; management expects R&D spending to rise further as the trial ramps in 2027.

Xeris Biopharma Price Performance

NASDAQ XERS traded up $0.57 during trading on Friday, reaching $7.93. The company’s stock had a trading volume of 2,251,719 shares, compared to its average volume of 1,886,183. The stock has a market capitalization of $1.37 billion, a PE ratio of 132.17 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a fifty day moving average of $7.64 and a 200 day moving average of $6.79. Xeris Biopharma has a one year low of $5.25 and a one year high of $10.08.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00. Following the completion of the sale, the insider directly owned 1,691,126 shares in the company, valued at $13,579,741.78. The trade was a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the sale, the director owned 126,500 shares of the company’s stock, valued at approximately $770,385. The trade was a 11.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 266,499 shares of company stock valued at $1,996,417 in the last ninety days. Insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LLC purchased a new position in Xeris Biopharma in the fourth quarter worth $84,000. VARCOV Co. purchased a new stake in Xeris Biopharma during the fourth quarter valued at about $243,000. Virtus Investment Advisers LLC raised its position in Xeris Biopharma by 44.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock valued at $291,000 after purchasing an additional 11,358 shares in the last quarter. Millennium Management LLC raised its position in Xeris Biopharma by 63.7% during the fourth quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock valued at $6,744,000 after purchasing an additional 334,302 shares in the last quarter. Finally, Man Group plc bought a new stake in Xeris Biopharma during the fourth quarter worth about $375,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.